Medivir AB - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments
SummaryMarketline's Medivir AB Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Medivir AB since January2007.
Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.
Key Highlights
This report includes Medivir AB's contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.
The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Medivir AB. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.
Scope
- Provides intelligence on Medivir AB's M&A, strategic partnerships and alliances, capital raising and private equity transactions.
- Detailed reports of various financial transactions undertaken by Medivir AB and its subsidiaries since 2007.
- Information about key financial and legal advisors for Medivir AB's financial deals transactions.
- Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.
Reasons to buy
- Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances.
- Form an independent opinion about Medivir AB’s growth strategies through the organic and inorganic activities undertaken since 2007.
- Track your competitors’ business structure and growth strategies.
Active Biotech AB focuses on pharmaceutical research and development in medical fields in which the immune system plays a central role. Co. has five projects in clinical development. Three of these projects involve the development of drugs for the treatment of autoimmune/inflammatory diseases. In the laquinimod project, Co. is developing a drug to address the indications multiple sclerosis, Crohn's disease and Lupus. Paquinimod is being developed to address systemic msclerosis, and RhuDex to address primary biliary cirrhosis and rheumatoid arthritis. The project portfolio also includes two drugs for treatment of the indications renal cell cancer (ANYARA) and prostate cancer (tasquinimod).
Karo Pharma Aktiebolag is an innovative drug discovery and development company specializing in the development of novel pharmaceuticals that target nuclear receptors. Nuclear receptors are also known as transcription factors and may be regarded as on/off buttons for production of proteins, such as enzymes and receptors. The nuclear receptors control biological processes at their core level, the genetic level. The natural hormones exert the body's own very tight control of protein production. By targeting nuclear receptors, Co. tunes the body's own control systems, for instance to normalize the metabolism of lipids in patients with elevated blood cholesterol.
Orexo is a pharmaceutical company and engaged in the development and commercialization of drugs based on patented drug delivery technologies primarily in Sweden and the United States. Co.'s product portfolio includes Zubsolv® tablets for maintenance treatment of opioid dependence; Abstral® for the treatment of breakthrough pain in cancer patients; Edluar®, an active substance zolpidem and for the treatment of short-term insomnia; Diabact UBT, which is used to diagnose the presence of Helicobacter pylori, a bacterium that causes gastric ulcers; and Heliprobe System, which is a doctor's office test to detect the presence of the gastric ulcer bacterium, Helicobacter pylori.
MarketLine, a world-leading provider of commercial intelligence, has over 400 experienced analysts, consultants, and researchers with regional and sector expertise in market sizing, competitor tracking, socio and macro economics, and business drivers.
For more than 15 years MarketLine has supported the research needs of investment banks, corporations, professional services firms, and academia with a unique mix of company, industry, country, city and financial data for every major industry and marketplace.
MarketLine’ holistic business intelligence report collection includes:
Industry Intelligence
‒ Industry Profiles
‒ Market Forecasts
‒ Porter’s Five Forces Analysis
Company Intelligence
‒ Company Profiles
‒ SWOT Analysis
‒ Financial Deals
Country and City Intelligence
‒ Country and City Profiles
‒ PEST/PESTLE Analysis
‒ Socio and macro-economic indicators
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.